0.9373 -0.01 (-0.81%)
After hours: 4:00PM EDT
|Bid||0.9400 x 900|
|Ask||0.9402 x 900|
|Day's Range||0.9400 - 0.9890|
|52 Week Range||0.5900 - 1.7800|
|Beta (3Y Monthly)||1.02|
|PE Ratio (TTM)||5.91|
|Earnings Date||Sep 12, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||5.75|
Teleconference and Webcast to be held on September 12, 2019 CRANBURY, N.J. , Sept. 12, 2019 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing ...
CRANBURY, N.J. , Sept. 11, 2019 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) will announce its fourth quarter and fiscal year end 2019 operating results on Thursday, September 12, 2019 ...
Palatin Technologies, Inc. (NYSEMKT:PTN) shareholders might understandably be very concerned that the share price has...
CRANBURY, N.J. , Aug. 6, 2019 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) announced today that it will be presenting at Canaccord Genuity's 39 th Annual Growth Conference on Wednesday, ...
Carl Spana became the CEO of Palatin Technologies, Inc. (NYSEMKT:PTN) in 2000. This analysis aims first to contrast...
"We accomplished our primary objectives of procuring FDA approval of Vyleesi and advancing our pipeline programs," said Carl Spana, Ph.D., President and Chief Executive Officer of Palatin. "The FDA approval is an incredible achievement for Palatin, and we are excited that premenopausal women now have a safe and effective, as-needed treatment option available to them for the treatment of HSDD.
on Monday jumped and then pulled back after the biopharma was cleared by the U.S. Food and Drug Administration to market a drug to treat weakened sexual desire in women. Palatin shares closed down 9.7% at $1.21. The FDA cleared Vyleesi, a treatment for premenopausal women with acquired generalized hypoactive sexual desire disorder, Palatin said.
Shares of Palatin Technologies Inc. rocketed 27% in very active premarket trading Monday, after a positive Food and Drug Administration decision on AMAG Pharmaceuticals Inc.'s treatment for hypoactive sexual desire disorder (HSDD) triggered a $60 million milestone payment. Trading volume was over 2.9 million shares, making Palatin's stock the most actively traded ahead of the open. The FDA granted marketing approval for AMAG's new drug application (NDA) for Vyleesi, which was developed by Palatin. AMAG's stock surged 8.1% ahead of the open. The company expects to receive the milestone payment in July. Based on the license agreement with AMAG, Palatin is also entitled to receive royalties on sales, ranging from high single-digit to low double-digit percentage ranges, and other milestone payments based on escalating annual sales thresholds. Palatin's stock has rallied 23% over the past 12 months and AMAG shares have tumbled 59%, while the S&P 500 has gained 7.1%.
The U.S. Food and Drug Administration late Friday approved a drug to treat low libido in women, and shares of the company slated to market the medication, AMAG Pharmaceuticals Inc. , shot more than 16% in the extended session. The drug, Vyleesi, is aimed at premenopausal women in whom low sex drive causes distress. It comes in an auto-injecting pen that can be used ahead of sexual activity. Vyleesi is expected to be commercially available in September. AMAG licensed Vyleesi from Palatin Technologies Inc. and under the terms of their agreement the FDA approval triggers a $60 million payment to Palatin, plus tiered royalties tied to sales milestones. Shares of Palatin rallied 30% in the extended session. Both stocks ended the regular trading day more than 4% higher.
CRANBURY, N.J., June 21, 2019 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) announced today that the U.S. Food and Drug Administration (FDA) has granted marketing approval of AMAG Pharmaceuticals, Inc.'s New Drug Application (NDA) for Vyleesi™ (bremelanotide injection), a melanocortin receptor agonist developed by Palatin indicated for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD). The FDA's approval of the NDA triggers a $60 million milestone payment to Palatin under its North American license agreement with AMAG.
The U.S. Food and Drug Administration on Friday approved Palatin Technologies Inc and Amag Pharmaceuticals Inc's drug to restore sexual desire in premenopausal women, Amag said. Analysts have said that a drug that safely and effectively treats loss of sexual desire in women could eventually reach annual sales approaching $1 billion.
CRANBURY, N.J., June 6, 2019 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today announced that the U.S. Food and Drug Administration (FDA) granted orphan drug designation for PL-8177 for the treatment of non-infectious intermediate, posterior, pan and chronic anterior uveitis. Non-infectious uveitis is a group of inflammatory diseases that produces swelling and destroys eye tissue and can result in vision loss.
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift...